Keyphrases
Alzheimer's Disease
100%
Imaging Results
100%
Long-term Safety
100%
Focused Ultrasound
100%
Cognitive Outcome
100%
Safety Outcomes
100%
Blood-brain Barrier Opening
100%
Ultrasound Treatment
54%
Brain Regions
36%
Hippocampus
36%
Entorhinal Cortex
27%
Blood-brain Barrier
27%
Mild Alzheimer's Disease
27%
Parietal Lobe
18%
Amyloid Plaques
18%
Frontal Lobe
18%
Neurodegenerative Diseases
9%
Clinical Outcomes
9%
Clinical Significance
9%
Disease Progression
9%
Serious Adverse Events
9%
Trial Participants
9%
Therapeutic Agents
9%
Adverse Consequences
9%
Large Cohort
9%
Treatment Session
9%
Brain Volume
9%
Alzheimer's Disease Pathology
9%
Mini-Mental State Examination
9%
Targeted Therapeutics
9%
Low-intensity Pulsed Ultrasound (LIPUS)
9%
Deep Brain
9%
Neurodegenerative Conditions
9%
Open-label Trial
9%
Magnetic Resonance-guided Focused Ultrasound (MRgFUS)
9%
Plaque Burden
9%
Cortical Brain
9%
MRI-guided
9%
Disease Assessment
9%
Positive Region
9%
PET Scan
9%
Outcome Assessment
9%
Ultrasound Sonication
9%
Alzheimer's Disease Neuroimaging Initiative
9%
Amyloid PET
9%
Florbetaben
9%
Centiloid Scale
9%
Medicine and Dentistry
Blood Brain Barrier
100%
Alzheimer's Disease
100%
Hippocampus
44%
Brain Region
44%
Amyloid
33%
Entorhinal Cortex
33%
Parietal Lobe
22%
Disease Exacerbation
22%
Amyloid Plaque
22%
Patient with Alzheimer's Disease
22%
Frontal Lobe
22%
Adverse Event
11%
Magnetic Resonance Imaging
11%
Therapeutic Agent
11%
Clinical Significance
11%
Outcome Assessment
11%
Targeted Therapy
11%
Neurodegenerative Disorder
11%
Positron Emission Tomography
11%
Positron Emission Tomography
11%
Open-Label Trial
11%
MR-guided Focused Ultrasound
11%
Mini-Mental State Examination Score
11%
Disease Assessment
11%
Florbetaben (18F)
11%
Neuroscience
Alzheimer's Disease
100%
Blood Brain Barrier
100%
Amyloid
55%
Hippocampus
44%
Entorhinal Cortex
33%
Frontal Lobe
22%
Magnetic Resonance Imaging
22%
Parietal Lobe
22%
Positron Emission Tomography
11%
Positron Emission Tomography
11%
Neurodegenerative Disorder
11%
Open-Label Trial
11%